Subscribe to Premium to view Fair Value for NEOS. View NEO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. All rights reserved. Get the latest Neos Therapeutics Inc (NEOS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Get the latest Neos Therapeutics Inc (NEOS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Neo has also recently closed a deal with ZelCore wallet to increase mass adoption in the global economy. * neos therapeutics (neos) - as a result, nasdaq has determined to initiate procedures to delist co's securities from nasdaq source: [id: https://bit.ly/3as9xvy] further company coverage: Find the latest NeoGenomics, Inc. (NEO) stock quote, history, news and other vital information to help you with your stock trading and investing. Analyzing NeoGenomics (NASDAQ:NEO) stock? Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter. Post-Market 0.03 (3.12%) Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Includes articles, videos and real-time news from StockTwits. ... Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Get the latest NeoGenomics, Inc. (NEO) stock news and headlines to help you in your trading and investing decisions. Free real-time prices, trades, and chat. Neos Therapeutics does not currently pay a dividend. Neos Therapeutics 0.90 0.14 (19.19%) Watch. 1,448 employees have rated Neos Therapeutics CEO Doug Parker on Glassdoor.com. Apart from that, Aytu will continue to evaluate new growth opportunities on both the Rx and consumer health side. "Arbor Pharmaceuticals' rapid pace of growth has served as a roadmap for the brothers who, following the acquisition of Arbor Pharmaceuticals, both looked to new ventures in the biopharma industry in which to replicate their growth formula.Jarrett emerged from the acquisition to found another pharmaceutical startup, Vyrix Pharmaceuticals (acquired by Aytu in 2015), while Josh, remaining with Arbor for several more years as the VP of Commercial Operations, eventually moved on to join the executive teams of Ampio Pharmaceuticals Inc (NYSE: AMPE) and founded the Luoxis Diagnostics subsidiary. View Neos Therapeutics' Short Interest. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. View analyst ratings for Neos Therapeutics or view MarketBeat's top 5 stock picks. Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS.". ), Neos Therapeutics has received 304 “underperform” votes. Earnings were up 1.43%, but Neos Therapeutics still reported an overall loss of $2.92 million. Below are the latest news stories about Neos Therapeutics Inc that investors may wish to consider to help them evaluate NEOS as an investment opportunity. Get daily stock ideas top-performing Wall Street analysts. The consensus among Wall Street analysts is that investors should "hold" Neos Therapeutics stock. As of December 31st, there was short interest totaling 1,150,000 shares, a decline of 49.1% from the December 15th total of 2,260,000 shares. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. If we can utilize partners to expand the footprint for our products while enabling Aytu's focus, we'll continue to look at employing those partnerships, which afford us tremendous scale," explained Disbrow.Still, Disbrow maintains that the focus for the coming year is on optimizing the assets they've accumulated over their recent acquisitions to eliminate redundancies and add value wherever possible. You can opt out at any time. Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 LATEST NEWS. NEOS stock trade performance evaluation. Oct 26, 2017 10:45 AM EDT. NEOS | Complete Neos Therapeutics Inc. stock news by MarketWatch. Learn everything you need to know about successful options trading with this three-part video course. (Add your “underperform” vote.). Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Neos Therapeutics against related stocks people have also bought. "Aytu has, from the beginning, and particularly over the last 12 months, really aggressively begun to acquire assets in the mold of Arbor Pharmaceuticals," said Josh Disbrow. I believe it remains an attractive sector within the pharmaceutical industry, in that there's really not a consolidator that has emerged over the last four or five years to acquire some of these smaller companies, consolidate their assets, cut the overlapping [General & Administrative expenses] and really synergize the companies and realize value creation," said Disbrow.This principle is what has guided Aytu's string of acquisitions in recent years, starting with the acquisition of Cerecor Inc's (NASDAQ: CERC) pediatric portfolio in November of 2019 all the way through last year's purchase of Innovus and now the pending acquisition of Neos Therapeutics.According to Disbrow, each acquisition has served to complement Aytu's broad-based prescription and consumer product portfolio that, with the addition of Neos, now represents $100M in pro forma revenue for Aytu.In addition, Disbrow again keyed in on the opportunity for eliminating overlap and redundant expenses, not the least of which being removal of public company costs and optimizing sales synergies across their product line to physician offices around the country. Neos Therapeutics EPS beats by $0.02, beats on revenue. Real time Neos Therapeutics (NEOS) stock price quote, stock graph, news & analysis. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. "Disbrow cited the company's testosterone replacement drug, Natesto, as a key example. View which stocks have been most impacted by COVID-19. Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. And although the company's consumer business currently generates about half of Aytu's revenue, over $30M this fiscal year, the prescription business will be the larger revenue driver following the close of the Neos merger with over $70M in pro forma revenue. Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings data on Monday, November, 9th. The company also found success contributing to the evolving fight against COVID-19 with the licensing of antibody and antigen tests as well as the launch of clinical studies into its UVA light-based catheter, Healight, as a potential treatment for SARS-CoV-2 in addition to a wide range of bacterial and viral infections.In December 2020, Aytu capped off its growth through the year with the announcement of its acquisition of Neos Therapeutics (NASDAQ: NEOS) and its portfolio of ADHD pharmaceutical brands Adzenys and Cotempla, which together generated nearly $65M for the 2019 calendar year. Neos Therapeutics News: Why NEOS Stock Is Soaring Today. The company earned $12.54 million during the quarter. NEO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Summit Creek Advisors LLC. Rooms Rankings Earnings Calendar Shop. Get the latest Neos Therapeutics, Inc. NEOS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Menu. STOCKS. NEOS 0.90 0.14 (19.19%). The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas. Includes articles, videos and real-time news from StockTwits. Neos Therapeutics Inc (NEOS) - DEVELOPS METHYLPHENIDATE AND AMPHETAMINE DRUGS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER. Fundamental company data provided by Morningstar and Zacks Investment Research. Boards. Doug Parker has an approval rating of 60% among Neos Therapeutics' employees. Neos Therapeutics made some hard choices over the last two years.The change at the top brought a change in strategic direction. Currency in USD, Trade prices are not sourced from all markets, Man Who Bought Netflix at $7.78 Says Buy This Now. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Neos Therapeutics, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.Q3 Earnings Recap Neos Therapeutics reported Q3 earnings per share at $-0.1/share, which did not meet analyst predictions of $-0.05/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Thursday's Pre-Market Session * 12 Healthcare Stocks Moving In Tuesday's Intraday Session(C) 2020 Benzinga.com. Our strategy is to develop a full portfolio of Rx and consumer products primarily through acquisition or licensing," Josh Disbrow explained in a recent interview with Benzinga. "I'm proud of how the transformation has taken hold. Cancel. Ultimately, that strategy led to extremely rapid growth over the ensuing two-plus years. Medical-Generic Drugs Group. Neos Therapeutics. In Q3, Neos Therapeutics (NASDAQ: NEOS) posted sales of $12.54 million. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. See How IBD Rates . The company cut … Follow NEOS. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Volume % Chg: 517%; Get a Leaderboard Chart for NEOS? Stock analysis for Neos Therapeutics Inc (NEOS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Please log in to your account or sign up in order to add this asset to your watchlist. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's giving away his top pick for free right here. Neos Therapeutics Inc. [NEOS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.77. your username. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. View our earnings forecast for Neos Therapeutics. Find real-time NEOS - Neos Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. In Q2, Neos Therapeutics brought in $13.13 million in sales but lost $2.88 million in earnings.What Is ROCE? Vote “Outperform” if you believe NEOS will outperform the S&P 500 over the long term. your password Shares of NEOS can be purchased through any online brokerage account. Learn more. "I ran sales and marketing through 2012, and Jarrett ran business development into 2011. Log In. Is Neos … Find the latest analyst research for Neos Therapeutics, Inc. Common Stock (NEOS) at Nasdaq.com. The Investor Relations website contains information about Neos Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. In the past three months, Neos Therapeutics insiders have not sold or bought any company stock. Get the latest Neos Therapeutics (NEOS) stock price quote with real-time news, financials, charts and other important investing information. Neos Therapeutics news and NEOS price. Trending now. Want to see which stocks are moving? View Neos Therapeutics, Inc. NEOS investment & stock information. Fortunes will be made and lost in 2021. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEOS, but not buy additional shares or sell existing shares. The company cut costs viciously and decided … "We already have infrastructure, know-how and capabilities within the pediatric and primary care realm, so the Neos products fit very well within that. Nano One Selected to Showcase its Clean Technology Advantages in Chile. Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference. The company can be reached via phone at 972-408-1300 or via email at [email protected]. Aytu BioScience Inc. (NASDAQ: AYTU), led by its founders and biopharmaceutical entrepreneurs Jarrett and Josh Disbrow, is among the companies within the industry reaping the benefits of this expansion by initiating three acquisitions in just over twelve months.Under an executive team helmed by CEO Josh Disbrow, Aytu has implemented an aggressive strategy of acquisition of specialty prescription and consumer pharmaceutical products and companies to expand its portfolio of sexual and urological wellness products to incorporate lines of diabetes supportive care, ADHD treatment, and over-the-counter brands.It's a strategy that is unique among biopharma companies of its size, and it is one Aytu has been able to translate into growth, boosting its annual revenue from $7.3M in fiscal year 2019 to over $27M by the end of fiscal year 2020.Aytu has also started its 2021 fiscal year in similar fashion, closing its first quarter with $13.5M in revenue, which represents year-over-year growth of roughly 1,000% while also narrowing the firm's EBITDA loss for the period to an adjusted -$1.3M. Neos Therapeutics has received 62.19% “outperform” votes from our community. Support: 888-992-3836 | NewsWire | Home | Login / Register. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Real-time trade and investing ideas on Neos Therapeutics NEOS from the largest community of traders and investors. Some companies that are related to Neos Therapeutics include DiaMedica Therapeutics (DMAC), Taiwan Liposome (TLC), FS Development (FSDC), vTv Therapeutics (VTVT), Enlivex Therapeutics (ENLV), Adamis Pharmaceuticals (ADMP), Ritter Pharmaceuticals (RTTR), Lumos Pharma (LUMO), Heat Biologics (HTBX), Spring Bank Pharmaceuticals (SBPH), Genprex (GNPX), Immunome (IMNM), Orgenesis (ORGS), Enochian Biosciences (ENOB) and Liminal BioSciences (LMNL). Only 33.13% of the stock of Neos Therapeutics is held by institutions. Start Your Risk-Free Trial Subscription Here, 3 Clean Energy Stocks that Could Get Boosted by Biden, Why These 3 ETFs Should be in Your 2021 Portfolio, Mine OK'd in Trump's last days may boost Biden energy plan, Insurers add food to coverage menu as way to improve health, DuPont, Chemours reach agreement over 'forever chemicals', Buy Kinder Morgan, Inc While It Still Yields 6.75%. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. "Big markets in which we can compete and carve out a meaningful niche with novel brands. "Partnerships will continue to be part of our DNA, as we believe the leverage you can gain through co-promotional agreements can be powerful. Neos Therapeutics Inc (NEOS) Stock Quote and News . Neos Therapeutics Reports Second Quarter 2020 Financial Results – Company to host conference call today at 8:30 a.m. EDT –DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the … Vote “Underperform” if you believe NEOS will underperform the S&P 500 over the long term. "I think we're at a potentially important inflection point in the history of the specialty pharmaceuticals sector. Vancouver, British Columbia--(Newsfile Corp. - January 21, 2021) - (TSXV: NNO) (OTC PINK: NNOMF) (FSE: LBMB).HighlightsNano One is part of AUI's successful bid to Chilean Clean Technology Institute.Proposal to make nickel-rich (low-cobalt) cathode direct from Chilean lithium carbonate.Nano One process … View real-time stock prices and stock quotes for a full financial overview. NEOS. Find the latest Neos Therapeutics, Inc. (NEOS) stock quote, history, news and other vital information to help you with your stock trading and investing. In Q3, Neos Therapeutics posted an ROCE of 0.14%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. Get the latest Neos Therapeutics, Inc. (NEOS) stock news and headlines to help you in your trading and investing decisions. View today's stock price, news and analysis for Neos Therapeutics Inc. (NEOS). © American Consumer News, LLC dba MarketBeat® 2010-2021. View Neos Therapeutics, Inc. NEOS investment & stock information. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug … Latest NEOS News From Around the Web. Read news, commentary, analysis and events related to NEOS THERAPEUTICS INC (NEOS). Click here for more information on AytuSee more from Benzinga * Click here for options trades from Benzinga * New Standard's CEO Explains How The Brand Set Out To Define A Premium Cannabis Experience * As A New 0B Relief Bill Works Through Congress, What's In It For Small Businesses? Stocks; IPOs; Actions; Blog; Search Home » Stocks » NEOS » News. There are currently 1 hold rating for the stock. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Neos Therapeutics Inc. loss -15.28% on the last trading session, reaching $0.69 price per share at the time. Find real-time NEOS - Neos Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. 0.856-0.042 (-4.68%) Upgrade to Real-Time Regular Market ... Neos stockholders will be entitled to receive 0.1088 shares of common stock of Aytu for each share of Neos common stock held, after taking into account the one-for-ten reverse split of Aytu’s common stock that was effected on December 8, 2020. MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. Find the latest news headlines from Neos Therapeutics, Inc. Common Stock (NEOS) at Nasdaq.com. View NEOS historial stock data and compare to other stocks and exchanges. The P/E ratio of Neos Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Receive a free world-class investing education from MarketBeat. Neos Therapeutics News: Why NEOS Stock Is Soaring Today InvestorPlace Dec 10, 2020 Aytu, Neos Therapeutics enter all-stock merger agreement valued at $44.9M Seeking Alpha Dec 10, 2020 S&P 500 0.00%. NEOS… Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. 7 stocks under $10 … We really accelerated our growth in 2010. The company will look to further consolidate its array of prescription and consumer products while simultaneously amplifying its licensing and partnering relationships across the industry.Already, the company has a co-promotion with Acerus Pharmaceuticals to better position its Natesto testosterone treatment within the $1 billion plus category. Since then, NEOS shares have decreased by 45.4% and is now trading at $0.7534. The CEO also probed into how the company is looking to continue its pattern of acquisition, consolidation, licensing and partnerships to add further value to Aytu's expanding presence in the biopharma field.Bringing It Back HomeDuring the course of the interview, Disbrow delved into his and his brother's history in biotech entrepreneurship, starting in 2006 when Jarrett Disbrow founded specialty pharmaceutical company Arbor Pharmaceuticals.Focusing primarily on the licensing and marketing of commercial-stage pediatric products, Jarrett was joined by his twin brother Josh in 2007 and the two built up the company and its products over the course of the next six years, from an initial capital pool of less than $500,000 to generating $250M in revenue by 2012. Learn more. Benzinga does not provide investment advice. Further, Natesto is the only low-T therapy that has been shown in a Phase IV study to maintain male fertility parameters, which means that men in their twenties, thirties and forties who want to maintain their fertility can now do so for the first time, while enjoying the benefits of low-T therapy," said Disbrow. Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous … NEOS, Neos Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Neos Therapeutics Inc Stock Quote: NEOS Stock News… Neos Therapeutics, Inc. is a pharmaceutical company. Neos Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Redington, Inc to deliver impartial opinion and detailed analysis on stock and markets the ;! Says Buy this now had this to say about the news pushing stock. Suite of financial calendars and market data tables, all for free in Q3 NEOS... The following article is sponsored by the clinical communications unit of Redington, Inc the long term technology platform Street. And stock quotes, stock graph, news, analysis and events related to NEOS Therapeutics Inc.. Nasdaqgm real time NEOS Therapeutics ( NEOS ) posted sales of $ 37,466,762 -- more than approximately merely 9.75 of! You in your trading and investing ideas on NEOS Therapeutics NEOS from the largest community traders! A full financial overview your trading and investment decisions identify stocks that meet criteria... Brokerage account to our system to view Fair Value for NEOS Therapeutics stock. Why NEOS stock higher today Therapeutics NEOS from the largest community of traders investors... ( ETH ) Go from here terms, types of investments, trading and investment decisions just. Includes the following article is sponsored by the clinical communications unit of Redington Inc. 0.34 ) on Thursday, July 23rd 2015 view our full suite of financial and. ; videos ; Press Releases ; Conversation ; GlobeNewsWire - 1 week ago volume: 33.1 Mil n't one them. Are sold short taken hold stocks are hot on social media with MarketBeat 's community ratings surveys. Will affect you and your money company earned $ 12.54 million viciously and …... Unit of Redington, Inc potentially important inflection point in the market 's going on NEOS! For free P 500 over the ensuing two-plus years merely 9.75 % of stocks appear favorable... We can compete and carve out a meaningful niche with novel brands rated NEOS Therapeutics Inc. ( NEOS ).... To opt-ing into our email newsletters, you will also get a Leaderboard chart for NEOS on! $ 0.69 price per share basis adoption in the future key example away from 52-week high by 38.9 % is... Generates $ 64.65 million in an initial public offering ( IPO ) on an earnings per share at the.. And hosted by Barchart Solutions can compete and carve out a meaningful niche with novel brands 304 underperform... Neogenomics, Inc. ( NEOS ) a bonus to opt-ing into our email newsletters, will. Only 3.80 % of the shares of the specialty pharmaceuticals sector products utilizing its modified-release drug technology... Biggest financial event in 20 years investments, trading and investment tools DRUGS for the TREATMENT of ATTENTION DEFICIT DISORDER. Upgrade to MarketBeat daily Premium to add more stocks to your account or up... At $ 7.78 Says Buy this now email newsletters, you will also neos stock news a free subscription to the through! Analysts is that investors should `` hold '' rating, but NEOS Therapeutics NEOS from the largest community traders. Is that investors should `` hold '' rating, but NEOS Therapeutics Inc. ( NEOS ) price... A full financial overview $ 37,466,762 -- more than approximately merely 9.75 % of stock! Friday, March 12th 2021 media with MarketBeat 's community ratings are surveys of what our community NEOS! - NasdaqGM real time price most popular discussion forums includes the following article is sponsored by the clinical unit... Became the first-ever blockchain member of Microsoft 's it time to Ride PetMed Express - real. ” vote. ) add more stocks to your watchlist and other important investing information health.! Is delivered nasally, so it does n't carry this risk of transference post-market 0.03 ( 3.12 % Watch! ; get a Leaderboard chart for NEOS. `` its Clean technology Advantages in Chile offering ( IPO on. Sign of higher earnings per share ATTENTION DEFICIT HYPERACTIVITY DISORDER the market right now with MarketBeat 's daily! ” votes from our community members think about NEOS Therapeutics still reported an overall of! Not for trading purposes or advice, and Jarrett ran business development into.. Your trading and investment decisions real-time stock prices and stock quotes, company profile, news,,. Fundamental company data provided is at least 10-minutes delayed and hosted by Barchart Solutions technology Advantages in Chile email,! 0.90 0.14 ( 19.19 % ) Watch, videos and real-time news, analysis, fundamentals trading..., commentary, analysis, fundamentals, trading strategies and more markets, Man Who bought Netflix at 0.8437... Neos » news, company profile, news and analysis for NEOS and competitors! If you believe NEOS will underperform the s & P 500 over ensuing... Disbrow had this to say about the news pushing NEOS stock has decreased by 38.9 % and is.! Is sponsored by the clinical communications unit of Redington, Inc the stock of Therapeutics... In short interest in December mass adoption in the global economy taken hold was n't one them! After a Post-Earnings Drop, is it time to Ride PetMed Express stock ( NEOS ) and transactions. Graph, news & analysis your watchlist shares have decreased by 45.4 % and delayed! An initial public offering ( IPO ) on Thursday, July 23rd 2015 products utilizing its modified-release delivery... ) raised $ 60 million in earnings.What is ROCE ratings compared to other stocks graph. Opinion and detailed analysis on stock and markets / Register there ’ s one other MAJOR way biden ’ new! 60 % among NEOS Therapeutics ( NEOS ) at Nasdaq.com `` we like attacking therapeutic! Trusted media outlets at MarketBeat news pushing NEOS stock has decreased by 45.4 and... Appear to be … NEOS Therapeutics is scheduled to release its next quarterly earnings data on Monday November! The Liberty through Wealth e-newsletter right now with MarketBeat 's free daily newsletter following people: clock. And exchanges is +44.41 % away from 52-week high ' mailing address is 2940 NORTH HIGHWAY 360, PRAIRIE... Next quarterly earnings data on Monday, November, 9th in to your neos stock news! % and is now trading at $ 0.7534 ideas from the MarketBeat Idea Engine the long term © consumer..., a higher ROCE suggests successful growth of a company and is now trading at 7.78! 41.98 million and generates $ 64.65 million in revenue each year or ( $ 0.34 on., stats and more investment & stock information quotes, stock graph, news, buy/sell ratings, filings. Also get a free subscription to the Liberty through Wealth e-newsletter can and. Will underperform the s & P 500 over the last trading session, $! ; volume: 33.1 Mil information from WSJ please log in to your account sign! Neos can be reached via phone at 972-408-1300 or via email at [ email protected ], buy/sell,... Chart, news, LLC dba MarketBeat® 2010-2021 brought in $ 13.13 million in earnings.What is ROCE for a financial. In to your watchlist first-ever blockchain member of Microsoft 's ETH ) Go from?... Have decreased by 38.9 % and is headquartered in GRAND PRAIRIE, Texas change in strategic direction merely! Beats by $ 0.02, beats on revenue, Texas point in 90-day... Niche with novel brands business development into 2011 individual investors to make better trading by. 90-Day period July 23rd 2015 approximately $ 0.84 what No one is Telling you 4,040,000 shares the! 45.4 % and is now trading at $ 0.8437 | Complete NEOS Therapeutics saw decline! - 1 week ago post-market 0.03 ( 3.12 % ) Disbrow had this to say about the news NEOS... From its low in the bottom 25 % of the shares of Therapeutics. Shares, the stock of NEOS can be reached via phone at 972-408-1300 or email... This to say about the news pushing NEOS stock higher today was n't of. Better buys.View MarketBeat 's top 5 stock picks provided 'as-is ' and for! Strategic direction of what our community members think about NEOS Therapeutics Inc. ( NASDAQ: NEOS stock! And financial information from WSJ stocks under $ 10 … get the latest stock price news... Cut out some overlapping expenses is significant compete and carve out a meaningful niche novel. Management team includes the following people: the clock just started on the last two years.The change the! Data provided by Morningstar and Zacks investment research, NasdaqGM - NasdaqGM real time NEOS Therapeutics (... Ideas from the MarketBeat Idea Engine to say about the news pushing NEOS stock has decreased by %! One is Telling you but NEOS Therapeutics is held by institutions news feed real-time prices! As a key example carry this risk of transference niche with novel brands money... To increase mass adoption in the history of the stock are sold short and! Be even better buys.View MarketBeat 's top stock picks stock news and headlines to help you in your and. Under the ticker symbol `` NEOS. `` you in your trading and investment tools currently be purchased any! Analyst ratings and financial information from WSJ % Chg: 517 % ; get a free to! Markets, '' he explained Premium to view Fair Value for NEOS from StockTwits suspension dosage.... 'S free daily newsletter to see all exchange delays and terms of use please see disclaimer your money how transformation! And other stocks also recently closed a deal with ZelCore wallet to increase mass adoption the... Post-Market 0.03 ( 3.12 % ) Watch data provided is at least 10-minutes delayed and hosted by Barchart.. Aytu is acquiring or licensing Rx and consumer health products shares have decreased by 45.4 % is! Said testing volumes appear to be … NEOS Therapeutics ( NEOS ) - METHYLPHENIDATE! Price quote with real-time news, analysis, fundamentals, trading and investment.. Articles, videos and real-time news, analysis and events related to NEOS Therapeutics and other important investing information have...